Clinical Trial Update: Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 trial of bevacizumab (Avastin) for unresectable or recurrent hemangioblastomas in Von Hippel-Lindau disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemangioblastomas
• Von Hippel-lindau Disease

Drugs mentioned

• Avastin (bevacizumab)

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Hemangioblastomas, Von Hippel Lindau Disease | EARLY_Phase 1 | Status: TERMINATED